Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.

被引：0

作者：

Reck, Martin

Kaiser, Rolf

Mellemgaard, Anders

Douillard, Jean Yves

Orlov, Sergey

Krzakowski, Maciej Jerzy

Von Pawel, Joachim

Gottfried, Maya

Bondarenko, Igor

Liao, Meilin

Barrueco, Jose

Gaschler-Markefski, Birgit

Novello, Silvia

机构：

[1] Grosshansdorf Hosp, Dept Thorac Oncol, Grosshansdorf, Germany

[2] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany

[3] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark

[4] Ctr Rene Gauducheau, Dept Med Oncol, F-44035 Nantes, France

[5] St Petersburg State Med Univ, Dept Thorac Oncol, St Petersburg, Russia

[6] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland

[7] Asklepios Fachkliniken Gauting, Pneumol Clin, Munich, Germany

[8] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel

[9] Municipal Inst Dnipropetrov, Dnepropetrovsk, Ukraine

[10] Shandong Prov Chest Hosp, Shanghai, Peoples R China

[11] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA

[12] Univ Turin, Dept Oncol, Turin, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA8011

引用

页数：1

共 50 条

[1] Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial.
Reck, Martin
Kaiser, Rolf
Mellerngaard, Anders
Douillard, Jean Yves
Orlov, Sergey
Krzakowski, Maciej Jerzy
Von Pawel, Joachim
Gottfried, Maya
Bondarenko, Igor
Liao, Meilin
Barrueco, Jose
Gaschler-Markefski, Birgit
Novello, Silvia
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] IMPACT OF TUMOR BURDEN ON THE OVERALL SURVIVAL ANALYSIS OF THE LUME-LUNG 1 STUDY: A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL OF NINTEDANIB (BIBF 1120) + DOCETAXEL IN NSCLC PATIENTS PROGRESSING AFTER FIRST-LINE CHEMOTHERAPY
Reck, Martin
Novello, Silvia
Mellemgaard, Anders
Orlov, Sergei
Kaiser, Rolf
Barrueco, Jose
Gaschler-Markefski, Birgit
Douillard, Jean-Yves
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S196 - S196
[3] Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial
Reck, M.
Mellemgaard, A.
Douillard, J. -Y.
Orlov, S.
Krzakowski, M.
von Pawel, J.
Gottfried, M.
Bondarenko, I.
Liao, M.
Barrueco, J.
Gaschler-Markefski, B.
Kaiser, R.
Novello, S.
LUNG CANCER, 2014, 83 : S12 - S12
[4] NINTEDANIB (BIBF 1120) + DOCETAXEL AS 2ND-LINE THERAPY IN PATIENTS WITH STAGE IIIB/IV OR RECURRENT NSCLC: RESULTS OF THE PHASE III, RANDOMISED, DOUBLE-BLIND LUME-LUNG 1 TRIAL. (FOR THE LUME-LUNG 1 STUDY GROUP)
Reck, M.
Mellemgaard, A.
Douillard, J.
Orlov, S.
Krzakowski, M.
von Pawel, J.
Gottfried, M.
Gaschler-Markefski, B.
Kaiser, R.
Novello, S.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S39 - S40
[5] Retrospective evaluation of the futility analysis in LUME Lung 2, a randomized, double-blind, placebo-controlled phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first line chemotherapy
Hanna, N.
Kaiser, R.
Kim, J. H.
Sullivan, R.
Aren, O.
Ahn, M. J.
Tiangco, B. J.
Voccia, I.
Barrueco, J.
Glomb, P.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S802 - S802
[6] Analysis of overall survival in adenocarcinoma NSCLC patients receiving 2nd line combination treatment with nintedanib (BIBF 1120) + docetaxel in the LUME-Lung 1 trial: A randomized, double-blind, placebo-controlled phase 3 study
Mellemgaard, A.
Kaiser, R.
Douillard, J. Y.
Orlov, S. V.
Krzakowski, M. J.
Von Pawel, J.
Gottfried, M.
Barrueco, J. R.
Hocke, J.
Reck, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S798 - S798
[7] Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.
Hanna, Nasser H.
Kaiser, Rolf
Sullivan, Richard N.
Aren, Osvaldo Rudy
Ahn, Myung-Ju
Tiangco, Beatrice
Zvirbule, Zanete
Barrios, Carlos H.
Demirkazik, Ahmet
Gaschler-Markefski, Birgit
Voccia, Isabelle
Barrueco, Jose
Kim, Joo-Hang
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC
Westeel, Virginie
Schuette, Wolfgang
Urban, Thierry
Radonjic, Dejan
von Wangenheim, Ute
Lorence, Robert M.
Reck, Martin
PLOS ONE, 2023, 18 (10):
[9] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC)
Herbst, Roy S.
Sun, Yan
Korfee, Soenke
Germonpre, Paul
Saijo, Nagahiro
Zhou, Caichun
Wang, Jie
Langmuir, Peter
Tada, Hiroomi
Kennedy, Sarah J.
Johnson, Bruce E.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S357 - S358
[10] Personalized peptide vaccination for castration resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo controlled, phase III trial.
Noguchi, Masanori
Fujimoto, Kiyohide
Arai, Gaku
Uemura, Hiroji
Hashine, Katsuyoshi
Matsumoto, Hiroaki
Fukasawa, Satoshi
Nakatsu, Hideomi
Takenaka, Atsushi
Fujisawa, Masato
Uemura, Hirotsugu
Naito, Seiji
Egawa, Shin
Fujimoto, Hiroyuki
Hinotsu, Shiro
Itoh, Kyogo
Kohjimoto, Yasuo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →